Securities code: 002294 securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022-005 Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Announcement on the acceptance of the listing application of ennasta tablets
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Recently, Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (hereinafter referred to as “the company”) submitted the application for listing of enaprost tablets, which was accepted by the State Drug Administration. The relevant information is hereby announced as follows:
1、 Basic information of drugs
Drug name: ennastatin tablets
Application item: registration and marketing license for domestically produced drugs
Drug type: Chemical
Acceptance No.: cyhs2102354, cyhs2102355, cyhs2102356
2、 Other relevant instructions
Ennastat tablet is an innovative oral small molecule preparation against renal anemia. The developed indication is renal anemia. Compared with the existing therapies, ennastat tablets have a clear mechanism to improve anemia, which can not only promote the production of endogenous erythropoietin, but also improve the utilization of iron; It has good safety and effectiveness, and can significantly improve patient compliance. The company introduced China from Japan Tobacco Inc. in December 2019. If it can be approved for listing, it is expected to be the second listed hif-phi drug in China. After listing, it will provide patients with more efficient and safe new treatment options.
According to the relevant registration regulations, the above-mentioned drug marketing application has been accepted and can not be put into production until it has passed the relevant review procedures of the State Drug Administration. According to the general industry characteristics, there is uncertainty in the listing of drugs, which will not have a significant impact on the company’s performance in the short term. The company will timely perform the obligation of information disclosure on relevant follow-up progress as required. Please invest rationally and pay attention to risks.
It is hereby announced
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) board of directors
January 4, 2002
